Drug repositioning for ATTR amyloidosis by interactome network corrected by Graph Neural Networks and transcriptome analysis

Amyloid transthyretin (ATTR) amyloidosis caused by transthyretin misfolded into amyloid deposits in nerve and heart is a progressive rare disease. The unknown pathogenesis and the lack of therapy make the 5-year survival prognosis extremely poor. Currently available ATTR drugs can only relieve symptoms and slow down progression, but no drug has demonstrated curable effective for this disease. The growing volume of pharmacological data and large-scale genome and transcriptome data bring …